

Hikma enters the French generic injectables market, expanding European presence

London, [13] June 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is pleased to announce the establishment of Hikma France S.A.S. (Hikma France). This marks Hikma's official entry into France, which has the second largest pharmaceutical market in Europe and a generic injectables hospital market of approximately \$2 billion¹.

To date, Hikma has supplied 21 generic injectable medicines to hospitals in France through a third-party. Following the approval of Hikma France and the opening of a new commercial office outside Paris, it will now supply medicines to hospitals directly. This broadened portfolio will span several therapeutic areas including anti-infective, cardiovascular and central nervous system.

Hikma has an established and growing presence in Europe with high-quality manufacturing plants in Portugal, Italy and Germany, supplying injectable products to North America, the Middle East and North Africa and Europe.

Riad Mishlawi, President of Hikma Injectables commented:

"The expansion into France is an important step forward in our European growth ambition. Hikma France will complement our existing presence in Europe. I am excited by the opportunity to supply French hospitals and their patients with high-quality and affordable injectable medicines. We look forward to building our presence here as we aim to become a key player in the French hospital market."

– ENDS –

Enquiries:

Hikma (Investors)

Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050
EVP, Strategic Planning and Global Affairs

Guy Featherstone +44 (0)20 3892 4389/ +44 7795 896738
Senior Investor Relations Manager

Layan Kalisse +44 (0)20 7399 2788/ +44 7970 709912
Investor Relations Analyst

Teneo (Press)

Charles Armitstead + 44 (0) 7703 330269
Camilla Cunningham + 44 (0) 7464 982426

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle

¹ Source: IQVIA FY 2021, generic injectable sales excluding biosimilars



East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2022 Hikma Pharmaceuticals PLC. All rights reserved.